A detailed history of Octagon Capital Advisors LP transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 1,273,333 shares of KALV stock, worth $17 Million. This represents 5.01% of its overall portfolio holdings.

Number of Shares
1,273,333
Previous 1,273,333 -0.0%
Holding current value
$17 Million
Previous $14.4 Million 6.81%
% of portfolio
5.01%
Previous 5.47%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$10.32 - $14.76 $997,603 - $1.43 Million
-96,667 Reduced 7.06%
1,273,333 $14.4 Million
Q1 2025

May 16, 2025

BUY
$7.4 - $12.6 $1.89 Million - $3.21 Million
255,000 Added 22.87%
1,370,000 $15.8 Million
Q1 2025

May 15, 2025

SELL
$7.4 - $12.6 $1.89 Million - $3.21 Million
-255,000 Reduced 18.61%
1,115,000 $12.9 Million
Q4 2024

Feb 14, 2025

BUY
$8.09 - $12.5 $11.1 Million - $17.1 Million
1,370,000 New
1,370,000 $11.6 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $328M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.